Scaling Pharmacovigilance Across Europe: Managing Local Requirements Without Losing Control

• Module I – Pharmacovigilance systems and quality systems, defining governance and oversight expectations
• Module II – Pharmacovigilance System Master File (PSMF), establishing documentation standards for PV systems
• Module VI – Case management and reporting requirements, governing the management and reporting of safety cases

Germany provides a clear example of how national pharmacovigilance requirements interact with the EU framework.

In addition to the EU Qualified Person for Pharmacovigilance (QPPV) required under GVP, German pharmaceutical law requires the designation of a Stufenplanbeauftragter, also referred to as the Graduated Plan Officer.

This role must:

• Reside within the European Union
• Remain continuously available
• Be formally notified to the competent authority such as BfArM

Germany also imposes additional regulatory obligations including:

• German-language communication requirements
• Systematic complaint recording obligations
• Authority notification in cases of quality defects that could lead to recalls or distribution restrictions

Furthermore, Germany requires an Information Officer, a role that operates beyond classical pharmacovigilance but interacts closely with PV and regulatory functions. This role must also be notified to authorities.

These elements demonstrate that even within a centralized EU pharmacovigilance framework, national governance layers remain essential.

France illustrates another dimension of national pharmacovigilance complexity.

Under the supervision of ANSM, the French system involves three key actors:

• Exploitant – the locally established company responsible for placing medicinal products on the market
• Responsible Pharmacist – holding ultimate accountability for regulatory compliance
• Local Pharmacovigilance Responsible Person – responsible for day-to-day PV implementation

The Local PV Responsible Person must:

• Reside in France
• Ensure compliance with both local and EU pharmacovigilance obligations
• Manage French-language communication with authorities
• Coordinate safety submissions to ANSM

This tripartite structure reinforces accountability and oversight but requires clear governance interfaces between headquarters, the EU QPPV, and local representatives.

Following Brexit, the United Kingdom has introduced further differentiation in its pharmacovigilance system.

The MHRA requires the designation of a National Contact Person for Pharmacovigilance (NCPP) when the EU QPPV is not based in the UK.

Companies must also maintain a UK-specific Pharmacovigilance System Master File (UK PSMF) that:

• Is electronically accessible within the UK
• Carries a unique UK PSMF number

Updates to the Summary of the Pharmacovigilance System must be submitted through the MHRA Submissions Portal within defined timelines.

In Northern Ireland, the Windsor Framework introduces a dual regulatory regime depending on product category, affecting reporting routes and regulatory responsibilities.

These developments illustrate how rapidly regulatory environments can evolve and why pharmacovigilance systems must remain adaptable.

Effective pharmacovigilance scaling typically involves four core steps:

1. Mapping national regulatory roles across all markets where products are marketed
2. Aligning local responsibilities with EU QPPV oversight structures
3. Integrating local reporting flows into centralized PV systems
4. Maintaining a PSMF that accurately reflects operational reality across territories

This governance approach allows companies to integrate local requirements without fragmenting their pharmacovigilance system.

A functional support model supplements internal pharmacovigilance teams with targeted expertise in specific countries.

This approach can address:

• Capacity gaps in local markets
• Temporary expansion phases
• Country-specific regulatory intelligence needs

Central governance remains in place while local expertise ensures compliance with national requirements.

A hybrid model retains strategic pharmacovigilance oversight internally while delegating operational tasks locally.

This structure typically involves:

• Central governance under the EU QPPV
• Local pharmacovigilance representatives or service providers
• Shared responsibility for operational pharmacovigilance activities

Hybrid models offer flexibility while maintaining clear accountability.

A full outsourcing model delegates end-to-end pharmacovigilance operations to a specialized partner while maintaining strategic oversight.

This structure typically involves:

• Central governance under the EU QPPV
• Local pharmacovigilance representatives or service providers
• Shared responsibility for operational pharmacovigilance activities

Full outsourcing models offer maximum scalability while preserving regulatory accountability.